News
Click here for news in Danish.
December 18, 2015 | Company Announcements
Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV VaccineDecember 08, 2015 | Company Announcements
Bavarian Nordic Introduces Incentive Program for all Employees and Issues Warrants to Executive Management and Certain EmployeesNovember 30, 2015 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/SNovember 16, 2015 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 03, 2015 | Company Announcements
Bavarian Nordic Announces Results of a Phase 1 Trial Investigating Brachyury Specific Cancer Vaccine in Patients with Advanced CancersNovember 03, 2015 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2015 October 28, 2015 | Company Announcements
Bavarian Nordic Announces Expansion of IMVAMUNE® Orders from Canadian Government October 28, 2015 | Press Releases
Bavarian Nordic Applauds Recommendations Outlined by U.S. Blue Ribbon Study Panel on Biodefense October 09, 2015 | Company Announcements
Bavarian Nordic Announces Initiation of Safety and Immunogenicity Study of Ebola Vaccine Regimen in Sierra LeoneSeptember 30, 2015 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/SSeptember 14, 2015 | Company Announcements
Bavarian Nordic Receives Contract Valued at USD 9 Million from Janssen as part of Advanced Development of Prime-Boost Ebola Vaccine RegimenSeptember 11, 2015 | Company Announcements
Bavarian Nordic issues Financial Calendar for 2016September 08, 2015 | Company Announcements
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of WarrantsAugust 25, 2015 | Company Announcements
Bavarian Nordic Announces First Half 2015 ResultsAugust 18, 2015 | Company Announcements
Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN® in Respiratory Syncitial Virus (RSV)August 05, 2015 | Company Announcements
Bavarian Nordic Announces the Resignation of James B. Breitmeyer as EVP and Chief Development Officer July 24, 2015 | Company Announcements
Bavarian Nordic Announces Initiation of NCI-sponsored Phase 2 Study of PROSTVAC in Patients with Localized Prostate CancerJuly 15, 2015 | Company Announcements
Bavarian Nordic Announces that the Oxford Vaccines Group has Initiated a Phase 2 Study of the Ebola Prime-Boost Vaccine Regimen Combining MVA-BN® Filo and Janssen’s AdVac® TechnologyJuly 07, 2015 | Company Announcements
Bavarian Nordic Receives Order for IMVAMUNE® Smallpox Vaccine from the U.S. Government Valued at USD 133 Million June 30, 2015 | Company Announcements
Bavarian Nordic Announces Option Exercise by U.S. Government for Development of Filovirus VaccineMay 31, 2015 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/SMay 21, 2015 | Press Releases
Members of the management and the board increase their share holdings in Bavarian Nordic A/SMay 18, 2015 | Company Announcements
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of WarrantsMay 13, 2015 | Company Announcements
Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE® Smallpox Vaccine